CLINICAL EVALUATION OF THE THERAPEUTIC EFFICACY OF SARVAKALPA-GHAN-VATI IN NON-ALCOHOLIC LIVER DISORDER.

Patanjali Research Institute0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1)Patients between the age group of 18-65 years will be selected.
•2)Patients irrespective of sex, religion, occupation and chronicity will be selected for the study.
•3)Both fresh and treated cases would be taken for the study.
•4)Patients with higher LFT levels than the upper limit of normal value will be selected.
•5)Patients with GRADE 1 and GRADE 2 fatty liver will be selected for the study.
•6)Patient with controlled Diabetes mellitus having GRADE 1 and GRADE 2 fatty liver will be selected for the study.

•1)Patients aged <18 years or >65 years will be excluded.
•2)Pregnant or lactating women will be excluded.
•3)Patients who had hepatitis B, C or other hepatic viral infection, autoimmune hepatitis and drug-induced hepatitis or alcoholic hepatitis will be excluded.
•4)Patients with severe complications of the cardiovascular, renal or hematopoietic systems and mental diseases will be excluded.
•5)Patients will be excluded having decompensated liver disease.
•6)Patients with prolonged or a history of ascites, developed hepato-cellular carcinoma, hepatic encephalopathy, variceal bleeding will be excluded.
•7)Patients with a history of using IFN or antiviral agents or corticosteroids or immunosuppressive drugs will also be excluded.
•8)Patients having GRADE 3 fatty liver disease will be excluded

发起方